Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q1 EPS by 15c
February 2, 2022 4:14 PM ESTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($0.60), $0.15 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $27.4 million versus the consensus estimate of $47.81 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
... More